Literature DB >> 24637549

Chemoprevention for neurofibromatosis 2: just over the horizon?

Scott R Plotkin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24637549      PMCID： PMC3956365          DOI： 10.1093/neuonc/nou037

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  15 in total

1.  Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset.

Authors:  Miriam J Smith; Jenny E Higgs; Naomi L Bowers; Dorothy Halliday; Joan Paterson; James Gillespie; Susan M Huson; Simon R Freeman; Simon Lloyd; Scott A Rutherford; Andrew T King; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  J Med Genet       Date:  2011-01-28       Impact factor: 6.318

2.  Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

Authors:  Darcy A Krueger; Marguerite M Care; Katherine Holland; Karen Agricola; Cynthia Tudor; Prajakta Mangeshkar; Kimberly A Wilson; Anna Byars; Tarek Sahmoud; David Neal Franz
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

3.  Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.

Authors:  Scott R Plotkin; Vanessa L Merker; Chris Halpin; Dominique Jennings; Michael J McKenna; Gordon J Harris; Fred G Barker
Journal:  Otol Neurotol       Date:  2012-08       Impact factor: 2.311

4.  Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.

Authors:  Scott R Plotkin; Chris Halpin; Michael J McKenna; Jay S Loeffler; Tracy T Batchelor; Fred G Barker
Journal:  Otol Neurotol       Date:  2010-09       Impact factor: 2.311

5.  Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Marc S Ballas; Krysten Brown; Annette O Nusbaum; Tsivia Hochman; Judith D Goldberg; Kevin M Koch; John G Golfinos; J Thomas Roland; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2012-07-27       Impact factor: 12.300

6.  NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

Authors:  Marianne F James; Sangyeul Han; Carolyn Polizzano; Scott R Plotkin; Brendan D Manning; Anat O Stemmer-Rachamimov; James F Gusella; Vijaya Ramesh
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

7.  ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.

Authors:  Joni K Doherty; Weg Ongkeko; Brianna Crawley; Ali Andalibi; Allen F Ryan
Journal:  Otol Neurotol       Date:  2008-01       Impact factor: 2.311

8.  Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

Authors:  Scott R Plotkin; Anat O Stemmer-Rachamimov; Fred G Barker; Chris Halpin; Timothy P Padera; Alex Tyrrell; A Gregory Sorensen; Rakesh K Jain; Emmanuelle di Tomaso
Journal:  N Engl J Med       Date:  2009-07-08       Impact factor: 91.245

9.  Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.

Authors:  D Lallemand; J Manent; A Couvelard; A Watilliaux; M Siena; F Chareyre; A Lampin; M Niwa-Kawakita; M Kalamarides; M Giovannini
Journal:  Oncogene       Date:  2008-11-24       Impact factor: 9.867

10.  Contact-dependent inhibition of EGFR signaling by Nf2/Merlin.

Authors:  Marcello Curto; Banumathi K Cole; Dominique Lallemand; Ching-Hui Liu; Andrea I McClatchey
Journal:  J Cell Biol       Date:  2007-06-04       Impact factor: 10.539
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.